Cheryl A. Pickett

581 total citations
20 papers, 365 citations indexed

About

Cheryl A. Pickett is a scholar working on Oncology, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, Cheryl A. Pickett has authored 20 papers receiving a total of 365 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 9 papers in Endocrinology, Diabetes and Metabolism and 5 papers in Molecular Biology. Recurrent topics in Cheryl A. Pickett's work include HER2/EGFR in Cancer Research (6 papers), Growth Hormone and Insulin-like Growth Factors (5 papers) and Advanced Breast Cancer Therapies (3 papers). Cheryl A. Pickett is often cited by papers focused on HER2/EGFR in Cancer Research (6 papers), Growth Hormone and Insulin-like Growth Factors (5 papers) and Advanced Breast Cancer Therapies (3 papers). Cheryl A. Pickett collaborates with scholars based in United States, France and Spain. Cheryl A. Pickett's co-authors include Arthur Gutierrez‐Hartmann, A Gutierrez-Hartmann, Kenneth A. Krohn, David A. Mankoff, Gary N. Mann, Nicole Manning, Paul E. Kinahan, Jeanne M. Link, David R. Byrd and Yoshiko Akita and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Molecular and Cellular Biology and Clinical Cancer Research.

In The Last Decade

Cheryl A. Pickett

19 papers receiving 358 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Cheryl A. Pickett United States 12 164 149 106 79 74 20 365
John F. Langenheim United States 11 97 0.6× 157 1.1× 187 1.8× 77 1.0× 93 1.3× 21 414
Mitsuo Itakura Japan 9 176 1.1× 155 1.0× 89 0.8× 43 0.5× 45 0.6× 15 378
Lone Frier Bovin Denmark 9 126 0.8× 171 1.1× 23 0.2× 65 0.8× 31 0.4× 11 376
Ruihua Luo China 13 109 0.7× 164 1.1× 45 0.4× 49 0.6× 50 0.7× 45 464
Arun Shastry India 11 69 0.4× 196 1.3× 29 0.3× 45 0.6× 59 0.8× 18 330
Chun‐Wai Ko Hong Kong 8 176 1.1× 154 1.0× 25 0.2× 21 0.3× 133 1.8× 10 344
Ricardo Renzo Brentani Brazil 11 95 0.6× 255 1.7× 21 0.2× 45 0.6× 76 1.0× 19 443
Marco Venanzoni Italy 9 135 0.8× 220 1.5× 56 0.5× 43 0.5× 95 1.3× 12 378
Els Louagie Belgium 6 69 0.4× 230 1.5× 20 0.2× 48 0.6× 133 1.8× 8 494
Ruifang Mi China 11 73 0.4× 158 1.1× 25 0.2× 37 0.5× 83 1.1× 17 341

Countries citing papers authored by Cheryl A. Pickett

Since Specialization
Citations

This map shows the geographic impact of Cheryl A. Pickett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheryl A. Pickett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheryl A. Pickett more than expected).

Fields of papers citing papers by Cheryl A. Pickett

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cheryl A. Pickett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheryl A. Pickett. The network helps show where Cheryl A. Pickett may publish in the future.

Co-authorship network of co-authors of Cheryl A. Pickett

This figure shows the co-authorship network connecting the top 25 collaborators of Cheryl A. Pickett. A scholar is included among the top collaborators of Cheryl A. Pickett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cheryl A. Pickett. Cheryl A. Pickett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shin, Sarah J., Geraldine O’Sullivan Coyne, Elizabeth K. Lee, et al.. (2023). Abstract B037: A pharmacodynamic pilot study of DS8201a in patients with HER2 expressing advanced solid tumors. Molecular Cancer Therapeutics. 22(12_Supplement). B037–B037.
2.
Lee, Elizabeth K., Andrea E. Wahner Hendrickson, Gerardo Colón‐Otero, et al.. (2023). Abstract B041: A phase 1 study of DS-8201a in combination with olaparib in HER2-expressing malignancies (CTEP #10355): Results of module 1 dose escalation. Molecular Cancer Therapeutics. 22(12_Supplement). B041–B041. 1 indexed citations
3.
Malvehy, Josep, Dirk Schadendorf, Ralf Gutzmer, et al.. (2021). Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma. Journal for ImmunoTherapy of Cancer. 9(3). e001621–e001621. 48 indexed citations
4.
Andtbacka, Robert H.I., Thomas Amatruda, John Nemunaitis, et al.. (2019). Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma. EBioMedicine. 47. 89–97. 47 indexed citations
5.
Kaufman, Peter A., Hans Wildiers, Gilles Freyer, et al.. (2018). Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer. Clinical Breast Cancer. 19(1). 47–57. 6 indexed citations
6.
7.
Dowlati, Afshin, Gordana Vlahovic, Ronald B. Natale, et al.. (2016). A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(18). 4574–4584. 16 indexed citations
8.
Kaufman, Peter A., Gilles Freyer, Margaret Kemeny, et al.. (2015). A phase 1b study of Trebananib plus Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in patients with HER2+ locally recurrent or metastatic breast cancer. Open Repository and Bibliography (University of Liège). 1 indexed citations
9.
Amin, Manik, Susan Minton, Patricia LoRusso, et al.. (2015). A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors. Investigational New Drugs. 34(1). 84–95. 35 indexed citations
10.
Wu, Benjamin, Erik Rasmussen, Lei Zhou, et al.. (2015). Pharmacokinetic drug–drug interaction assessment of peptibody trebananib in combination with chemotherapies. Cancer Chemotherapy and Pharmacology. 76(2). 243–250. 1 indexed citations
11.
12.
Mann, Gary N., Jeanne M. Link, Cheryl A. Pickett, et al.. (2006). [11C]Metahydroxyephedrine and [18F]Fluorodeoxyglucose Positron Emission Tomography Improve Clinical Decision Making in Suspected Pheochromocytoma. Annals of Surgical Oncology. 13(2). 187–197. 50 indexed citations
13.
Gilliam, Lisa K., Aimee D. Kohn, Tasneem Lalani, et al.. (2006). Capecitabine Therapy for Refractory Metastatic Thyroid Carcinoma: A Case Series. Thyroid. 16(8). 801–810. 16 indexed citations
14.
Pickett, Cheryl A.. (2006). An Unusual Case of Central Hypothyroidism and Thyrotoxicosis Factitia. The Endocrinologist. 16(4). 219–222. 1 indexed citations
15.
Pickett, Cheryl A.. (2005). Update on the medical management of pituitary adenomas. Current Neurology and Neuroscience Reports. 5(3). 178–185. 3 indexed citations
16.
Pickett, Cheryl A., et al.. (2005). Altered Expression of Cyclins and Cell Cycle Inhibitors in Papillary Thyroid Cancer: Prognostic Implications. Thyroid. 15(5). 461–473. 16 indexed citations
17.
Pickett, Cheryl A.. (2003). Diagnosis and management of pituitary tumors: recent advances. Primary Care Clinics in Office Practice. 30(4). 765–789. 18 indexed citations
18.
Pickett, Cheryl A., Nicole Manning, Yoshiko Akita, & Arthur Gutierrez‐Hartmann. (2002). Role of Specific Protein Kinase C Isozymes in Mediating Epidermal Growth Factor, Thyrotropin-Releasing Hormone, and Phorbol Ester Regulation of the Rat Prolactin Promoter in GH4/GH4C1 Pituitary Cells. Molecular Endocrinology. 16(12). 2840–2852. 22 indexed citations
19.
Pickett, Cheryl A. & Arthur Gutierrez‐Hartmann. (1995). Epidermal Growth Factor and Ras Regulate Gene Expression in GH4 Pituitary Cells by Separate, Antagonistic Signal Transduction Pathways. Molecular and Cellular Biology. 15(12). 6777–6784. 19 indexed citations
20.
Pickett, Cheryl A. & A Gutierrez-Hartmann. (1994). Ras mediates Src but not epidermal growth factor-receptor tyrosine kinase signaling pathways in GH4 neuroendocrine cells.. Proceedings of the National Academy of Sciences. 91(18). 8612–8616. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John F. Langenheim Breakdown of academic impact, for papers by Mitsuo Itakura Breakdown of academic impact, for papers by Lone Frier Bovin Breakdown of academic impact, for papers by Ruihua Luo Breakdown of academic impact, for papers by Arun Shastry Breakdown of academic impact, for papers by Chun‐Wai Ko Breakdown of academic impact, for papers by Ricardo Renzo Brentani Breakdown of academic impact, for papers by Marco Venanzoni Breakdown of academic impact, for papers by Els Louagie Breakdown of academic impact, for papers by Ruifang Mi
Rankless by CCL
2026